Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp., a pioneer in drug delivery platforms, has been granted two new US patents for treating hypertension and epilepsy, expanding its patent portfolio to 43 worldwide. The patents are based on the company’s DehydraTECH technology, which has shown promise in enhancing the delivery and effectiveness of cannabidiol (CBD) for medical treatments. Lexaria’s ongoing commitment to innovation is underscored by its substantial intellectual property assets and dedication to improving oral drug delivery.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
